 New York, New York--Newsfile Corp. - February 9, 2021 - PCG Digital: Soligenix NASDAQ: SNGX continues to build excitement for its SGX301 candidate following strong Phase 3 data and commercialization plans. The company recently held an investor webcast to further explain the companys plans for commercializing its ground-breaking SGX301 candidate for the treatment of cutaneous T-cell lymphoma CTCL. Here are some key takeaways from the commercialization QA: 1. Soligenix will commercialize SGX301 in the U.S... 